Unfortunately, 20% of patients diagnosed with CRC have metastatic disease.1 The recurrence of CRC is mostly a time‐limited phenomenon; 40%‐50% of recurrence events become apparent within the first year after the initial surgical resection.2 In addition, the earlier the relapse occurs, the poorer are the overall survival rates.3 The growth and proliferation of metastatic CRC (mCRC) depends essentially on two signalling pathways: the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. This evidence concerns the gene VEGFA and metastatic neoplasm.